Pharmacodynamics of NN2211, a novel long acting GLP-1 derivative

What Was Tested

The paper reports a study of Glucagon and Liraglutide, published as a randomized controlled trial.

To evaluate the effects of NN2211, a GLP-1 derivative, on glucose and insulin homeostasis in healthy volunteers by use of a nonlinear mixed-effects modeling approach.

Who Took Part

The age groups tagged for this paper are adults, men only.

NN2211 is a GLP-1 derivative intended for the treatment of type 2 diabetes.

Since NN2211 is only intended to have an effect when glucose levels are above baseline (thus limiting the risk of hypoglycaemia), no effects would be expected in healthy volunteers.

How the Study Was Run

In design terms this was a randomized, double-blind and placebo-controlled study.

The participants were allocated by chance, so the Glucagon group and the comparison group should start out alike.

Blinding on both sides kept the participants and researchers unaware of who received Glucagon.

A placebo (an inactive look-alike) gave the Glucagon group a baseline to be compared against.

After an initial model-building phase, the first-order approximation to the likelihood available in NONMEM was used to model the data.

Placebo-dosed subjects were included in the analysis.

What Was Measured

PubMed files the paper under topics including Blood Glucose, Glucagon, Glucagon-Like Peptide 1, Insulin, Liraglutide, Nonlinear Dynamics and Peptide Fragments.

What This Means in Plain Language

The paper is a randomized, double-blind and placebo-controlled study of Glucagon and Liraglutide.

Results are reported in around 2 sentences of the abstract; we leave them to the paper itself rather than summarise them.

The publication is from 2003 (European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences), a journal based in Netherlands.

More context: the Glucagon compound page and the Liraglutide compound page.